The U.S. Supreme Court has temporarily restored nationwide access to mifepristone by mail, pausing a Fifth Circuit decision that would have reinstated in-person dispensing requirements, providing critical relief for patients and providers.
The National Abortion Federation has criticized the Fifth Circuit’s decision in Louisiana v. FDA, stating that it will create medically unnecessary barriers to abortion care and disregards the well-established safety and efficacy of mifepristone via telehealth.
LOUISIANA — On Friday, Louisiana became the first state to classify the abortion pills, misoprostol and mifepristone,…